ID   FABP6_HUMAN             Reviewed;         128 AA.
AC   P51161; Q07DR7; Q8TBI3; Q9UGI7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   07-APR-2021, entry version 185.
DE   RecName: Full=Gastrotropin;
DE            Short=GT;
DE   AltName: Full=Fatty acid-binding protein 6;
DE   AltName: Full=Ileal lipid-binding protein;
DE            Short=ILBP;
DE   AltName: Full=Intestinal 15 kDa protein;
DE            Short=I-15P;
DE   AltName: Full=Intestinal bile acid-binding protein;
DE            Short=I-BABP;
GN   Name=FABP6; Synonyms=ILBP, ILLBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Ileum;
RX   PubMed=7619861; DOI=10.1016/0005-2760(95)00098-w;
RA   Oelkers P., Dawson P.A.;
RT   "Cloning and chromosomal localization of the human ileal lipid-binding
RT   protein.";
RL   Biochim. Biophys. Acta 1257:199-202(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), BILE ACID-BINDING, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Ileum;
RX   PubMed=7588781; DOI=10.1111/j.1432-1033.1995.406_2.x;
RA   Fujita M., Fujii H., Kanda T., Sato E., Hatakeyama K., Ono T.;
RT   "Molecular cloning, expression, and characterization of a human intestinal
RT   15-kDa protein.";
RL   Eur. J. Biochem. 233:406-413(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), ALTERNATIVE
RP   PROMOTER USAGE, SUBCELLULAR LOCATION, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17909007; DOI=10.1158/0008-5472.can-06-3690;
RA   Fang C., Dean J., Smith J.W.;
RT   "A novel variant of ileal bile acid binding protein is up-regulated through
RT   nuclear factor-kappaB activation in colorectal adenocarcinoma.";
RL   Cancer Res. 67:9039-9046(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [5]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS
RP   HIS-33 AND TYR-55.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19 (ISOFORM 1).
RA   Barley N.F., Shaw-Smith C.J., Chakravarty P., Howard A., Legon S.,
RA   Walters J.R.;
RT   "The human ileal bile acid binding protein gene: promoter sequence and
RT   effects of CDX2 on expression.";
RL   Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   BILE ACID-BINDING.
RX   PubMed=11461829; DOI=10.1016/s1357-2725(01)00070-x;
RA   Zimmerman A.W., van Moerkerk H.T., Veerkamp J.H.;
RT   "Ligand specificity and conformational stability of human fatty acid-
RT   binding proteins.";
RL   Int. J. Biochem. Cell Biol. 33:865-876(2001).
RN   [8]
RP   STRUCTURE BY NMR IN COMPLEX WITH TAUROCHOLATE, AND DOMAIN.
RX   PubMed=12486725; DOI=10.1002/prot.10289;
RA   Kurz M., Brachvogel V., Matter H., Stengelin S., Thuering H., Kramer W.;
RT   "Insights into the bile acid transportation system: the human ileal lipid-
RT   binding protein-cholyltaurine complex and its comparison with homologous
RT   structures.";
RL   Proteins 50:312-328(2003).
RN   [9]
RP   STRUCTURE BY NMR IN COMPLEX WITH GLYCOCHOLATE AND GLYCOCHENODEOXYCHOLATE,
RP   AND DOMAIN.
RX   PubMed=26613247; DOI=10.1111/febs.13610;
RA   Horvath G., Bencsura A., Simon A., Tochtrop G.P., DeKoster G.T.,
RA   Covey D.F., Cistola D.P., Toke O.;
RT   "Structural determinants of ligand binding in the ternary complex of human
RT   ileal bile acid binding protein with glycocholate and
RT   glycochenodeoxycholate obtained from solution NMR.";
RL   FEBS J. 283:541-555(2016).
RN   [10]
RP   VARIANT MET-79.
RX   PubMed=19744871; DOI=10.1016/j.ymgme.2009.08.001;
RA   Fisher E., Grallert H., Klapper M., Pfaefflin A., Schrezenmeir J.,
RA   Illig T., Boeing H., Doering F.;
RT   "Evidence for the Thr79Met polymorphism of the ileal fatty acid binding
RT   protein (FABP6) to be associated with type 2 diabetes in obese
RT   individuals.";
RL   Mol. Genet. Metab. 98:400-405(2009).
CC   -!- FUNCTION: Binds to bile acids and is involved in enterohepatic bile
CC       acid metabolism. Required for efficient apical to basolateral transport
CC       of conjugated bile acids in ileal enterocytes (By similarity). In vitro
CC       binds to bile acids in the order: deoxycholic acid > cholic acid >
CC       chenodeoxycholic acid and respective BA conjugation modifies affinities
CC       in the order taurine-conjugated > glycine-conjugated > unconjugated
CC       bile acids. Stimulates gastric acid and pepsinogen secretion (By
CC       similarity). {ECO:0000250|UniProtKB:P10289,
CC       ECO:0000250|UniProtKB:P51162, ECO:0000269|PubMed:12486725,
CC       ECO:0000269|PubMed:7588781}.
CC   -!- FUNCTION: [Isoform 2]: Essential for the survival of colon cancer cells
CC       to bile acid-induced apoptosis. {ECO:0000269|PubMed:17909007}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm
CC       {ECO:0000250|UniProtKB:P80020}. Membrane; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P50119}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:P50119}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:17909007}. Note=Localized close to nucleus on the
CC       apical side of both normal and neoplastic cells.
CC       {ECO:0000269|PubMed:17909007}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=1;
CC         IsoId=P51161-1; Sequence=Displayed;
CC       Name=2; Synonyms=IBABP-L;
CC         IsoId=P51161-2; Sequence=VSP_038039;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in the jejunum, ileum, cecum
CC       and ascending colon intestine. Isoform 2 is xpressed in the
CC       gallbladder, duodenum, jejunum, ileum, cecum, ascending, transverse and
CC       descending colon, sigmoid colon and rectum. Isoform 2 is expressed in
CC       colorectal adenocarcinomas and their adjacent normal mucosa (at protein
CC       level). {ECO:0000269|PubMed:17909007, ECO:0000269|PubMed:7588781,
CC       ECO:0000269|PubMed:7619861}.
CC   -!- INDUCTION: Isoform 1 is up-regulated by chenodeoxycholic acid (CDCA)
CC       via the FXR transcription pathway. Isoform 2 is up-regulated by NF-
CC       kappa-B and in all stages of colorectal adenocarcinoma. Isoform 1 is
CC       not up-regulated in all stages of colorectal adenocarcinoma.
CC       {ECO:0000269|PubMed:17909007}.
CC   -!- DOMAIN: Forms a beta-barrel structure that accommodates the hydrophobic
CC       ligand in its interior. Can bind at least two ligands per molecule,
CC       however, the stoichiometry is debated. {ECO:0000305|PubMed:12486725,
CC       ECO:0000305|PubMed:26613247}.
CC   -!- SIMILARITY: Belongs to the calycin superfamily. Fatty-acid binding
CC       protein (FABP) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH22489.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U19869; AAB82751.1; -; mRNA.
DR   EMBL; X90908; CAA62415.1; -; mRNA.
DR   EMBL; DQ132786; ABA12611.1; -; mRNA.
DR   EMBL; AC008609; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC112191; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022489; AAH22489.1; ALT_INIT; mRNA.
DR   EMBL; AJ250902; CAB65728.1; -; Genomic_DNA.
DR   CCDS; CCDS43393.1; -. [P51161-2]
DR   CCDS; CCDS4349.1; -. [P51161-1]
DR   PIR; S63983; S63983.
DR   RefSeq; NP_001035532.1; NM_001040442.1. [P51161-2]
DR   RefSeq; NP_001124430.1; NM_001130958.1. [P51161-2]
DR   RefSeq; NP_001436.1; NM_001445.2. [P51161-1]
DR   PDB; 1O1U; NMR; -; A=2-128.
DR   PDB; 1O1V; NMR; -; A=2-128.
DR   PDB; 2MM3; NMR; -; A=2-128.
DR   PDB; 5L8I; X-ray; 1.88 A; A/B/C=1-128.
DR   PDB; 5L8N; X-ray; 2.12 A; A/B/C=1-128.
DR   PDB; 5L8O; X-ray; 2.39 A; A/B/C=1-128.
DR   PDBsum; 1O1U; -.
DR   PDBsum; 1O1V; -.
DR   PDBsum; 2MM3; -.
DR   PDBsum; 5L8I; -.
DR   PDBsum; 5L8N; -.
DR   PDBsum; 5L8O; -.
DR   BMRB; P51161; -.
DR   SMR; P51161; -.
DR   STRING; 9606.ENSP00000377549; -.
DR   DrugBank; DB02659; Cholic Acid.
DR   DrugBank; DB02691; Glycocholic acid.
DR   DrugBank; DB04348; Taurocholic acid.
DR   SwissLipids; SLP:000001518; -.
DR   iPTMnet; P51161; -.
DR   PhosphoSitePlus; P51161; -.
DR   BioMuta; FABP6; -.
DR   DMDM; 1708457; -.
DR   EPD; P51161; -.
DR   jPOST; P51161; -.
DR   MassIVE; P51161; -.
DR   MaxQB; P51161; -.
DR   PaxDb; P51161; -.
DR   PeptideAtlas; P51161; -.
DR   PRIDE; P51161; -.
DR   ProteomicsDB; 56292; -. [P51161-1]
DR   ProteomicsDB; 56293; -. [P51161-2]
DR   Antibodypedia; 1989; 239 antibodies.
DR   DNASU; 2172; -.
DR   Ensembl; ENST00000393980; ENSP00000377549; ENSG00000170231. [P51161-2]
DR   Ensembl; ENST00000402432; ENSP00000385433; ENSG00000170231. [P51161-1]
DR   GeneID; 2172; -.
DR   KEGG; hsa:2172; -.
DR   UCSC; uc003lxx.2; human. [P51161-1]
DR   CTD; 2172; -.
DR   DisGeNET; 2172; -.
DR   GeneCards; FABP6; -.
DR   HGNC; HGNC:3561; FABP6.
DR   HPA; ENSG00000170231; Tissue enriched (intestine).
DR   MIM; 600422; gene.
DR   neXtProt; NX_P51161; -.
DR   OpenTargets; ENSG00000170231; -.
DR   PharmGKB; PA27962; -.
DR   VEuPathDB; HostDB:ENSG00000170231.15; -.
DR   eggNOG; KOG4015; Eukaryota.
DR   GeneTree; ENSGT00940000157139; -.
DR   HOGENOM; CLU_113772_4_0_1; -.
DR   InParanoid; P51161; -.
DR   OMA; MAFSGKW; -.
DR   OrthoDB; 1440574at2759; -.
DR   PhylomeDB; P51161; -.
DR   TreeFam; TF330348; -.
DR   PathwayCommons; P51161; -.
DR   Reactome; R-HSA-159418; Recycling of bile acids and salts.
DR   Reactome; R-HSA-163560; Triglyceride catabolism.
DR   Reactome; R-HSA-9623433; NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis.
DR   BioGRID-ORCS; 2172; 2 hits in 985 CRISPR screens.
DR   ChiTaRS; FABP6; human.
DR   EvolutionaryTrace; P51161; -.
DR   GeneWiki; FABP6; -.
DR   GenomeRNAi; 2172; -.
DR   Pharos; P51161; Tbio.
DR   PRO; PR:P51161; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P51161; protein.
DR   Bgee; ENSG00000170231; Expressed in small intestine Peyer's patch and 147 other tissues.
DR   ExpressionAtlas; P51161; baseline and differential.
DR   Genevisible; P51161; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0030522; P:intracellular receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006629; P:lipid metabolic process; NAS:ProtInc.
DR   GO; GO:0006869; P:lipid transport; IEA:UniProtKB-KW.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0019433; P:triglyceride catabolic process; TAS:Reactome.
DR   Gene3D; 2.40.128.20; -; 1.
DR   InterPro; IPR012674; Calycin.
DR   InterPro; IPR000463; Fatty_acid-bd.
DR   InterPro; IPR031259; ILBP.
DR   PANTHER; PTHR11955; PTHR11955; 1.
DR   PRINTS; PR00178; FATTYACIDBP.
DR   SUPFAM; SSF50814; SSF50814; 1.
DR   PROSITE; PS00214; FABP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative promoter usage; Cytoplasm;
KW   Lipid transport; Lipid-binding; Membrane; Reference proteome; Transport.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P10289"
FT   CHAIN           2..128
FT                   /note="Gastrotropin"
FT                   /id="PRO_0000067380"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P10289"
FT   VAR_SEQ         1
FT                   /note="M -> MKTVTMMMVVEMQALTQVLRAVLSACTWVSRKGDLQRMKQTHKGKPP
FT                   SSM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17909007"
FT                   /id="VSP_038039"
FT   VARIANT         33
FT                   /note="R -> H (in dbSNP:rs17856662)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_039578"
FT   VARIANT         55
FT                   /note="S -> Y (in dbSNP:rs17852045)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_039579"
FT   VARIANT         79
FT                   /note="T -> M (may be associated with type 2 diabetes obese
FT                   individuals; dbSNP:rs1130435)"
FT                   /evidence="ECO:0000269|PubMed:19744871"
FT                   /id="VAR_039580"
FT   STRAND          5..14
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   HELIX           15..22
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   HELIX           26..33
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          37..44
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          47..54
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   TURN            55..57
FT                   /evidence="ECO:0007744|PDB:5L8O"
FT   STRAND          59..65
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          68..72
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          75..77
FT                   /evidence="ECO:0007744|PDB:5L8N"
FT   STRAND          80..83
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          85..87
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          90..95
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          98..104
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          106..115
FT                   /evidence="ECO:0007744|PDB:5L8I"
FT   STRAND          118..127
FT                   /evidence="ECO:0007744|PDB:5L8I"
SQ   SEQUENCE   128 AA;  14371 MW;  173CBC5DBEDADDE1 CRC64;
     MAFTGKFEME SEKNYDEFMK LLGISSDVIE KARNFKIVTE VQQDGQDFTW SQHYSGGHTM
     TNKFTVGKES NIQTMGGKTF KATVQMEGGK LVVNFPNYHQ TSEIVGDKLV EVSTIGGVTY
     ERVSKRLA
//
